Navigation Links
Gene Therapy Improves Vision in Patients with Congenital Retinal Disease
Date:4/27/2008

he Second University of Naples, an institution with long-standing experience in collecting and studying patients with inherited retinal diseases, under the supervision of Francesca Simonelli, M.D.

Testing continued over a period of six months following the gene therapy vector administration. One patient was better able to navigate an obstacle course compared to before the injection. The patients also had less nystagmus, an involuntary movement of the eyes that is common in LCA. In the patient who experienced better vision even in the uninjected eye, the researchers suggest that the reduced nystagmus benefited both eyes.

"The current clinical trial will continue with more patients and with ongoing follow-up to monitor results," said Bennett. "We expect improvements to be more pronounced if treatment occurs in childhood, before the disease progresses."

"This result is important for the entire field of gene therapy," notes High, a past president of the American Society of Gene Therapy. "Gene transfer has been in clinical trials for over 15 years now, and although it has an excellent safety record, examples of therapeutic effect are still relatively few. The results in this study provide objective evidence of improvement in the ability to perceive light, and thus lay the groundwork for future studies in this and other retinal disorders," said High.

The pace of moving from pre-clinical discoveries into clinical trials has typically been slow in the field of gene therapy due to the breadth of expertise required, ranging from in-depth knowledge of the disorder to detailed understanding of vector design, manufacture, and pre-clinical evaluation. The complexities of regulatory oversight at both the federal and local levels also present challenges. Through the Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia has developed concentrated expertise and substantial resources to facilitate the "bench to beds
'/>"/>

SOURCE The Children's Hospital of Philadelphia; University ofPennsylvania
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Gene Therapy Provides Vision to People who Were Nearly Blind
2. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
3. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
4. In Blood Vessel Stents, Innovative Materials Allow Better Control, Delivery of Gene Therapy
5. Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells
6. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
7. MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
8. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
9. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
10. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
11. NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... MOUNT PROSPECT, Ill. , July 31, 2015 ... of Pharmacy ® (NABP ® ) issued ... charged with ensuring that action is taken against ... the Internet Drug Outlet Identification Program ... 2015 , thousands of websites ...
(Date:7/31/2015)... Fla. , July 31, 2015  Xcelience, ... today that it has made a structured cash ... -based company specializing in milling, micronization and powder ... will help grow Powdersize,s business while simultaneously adding ... to Xcelience,s portfolio of capabilities. ...
(Date:7/31/2015)... -- Xencor, Inc. (NASDAQ: XNCR ), a clinical-stage biopharmaceutical ... autoimmune diseases, asthma and allergic diseases, and cancer, today ... to its board of directors. "Yujiro,s ... a tremendous asset to our board," said Bassil ... Xencor. "Xencor faces a range of opportunities for our ...
Breaking Medicine Technology:NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... Germany, April 25, 2007-Labtec GmbH (Langenfeld,Germany), a ... multiple dose clinical study for their proprietary,Sufentanil ... to announce the successful,completion of the second ... for this program was to complete this ...
... At Least 10 Genetic Variants Are Associated,With Adult ... – In the most,comprehensive look at genetic risk ... team, working in close collaboration with two,other groups, ... with increased risk of diabetes and confirmed existence,of ...
Cached Medicine Technology:Labtec’s Next Generation Pain Patch Successful in Clinical,Studies 2Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 2Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 3Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 4Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 5Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 6Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 7
(Date:8/2/2015)... , ... August 03, 2015 , ... ... will be attending and exhibiting at the Association for Healthcare Documentation Integrity’s (AHDI) ... , “We are pleased for the opportunity the AHDI conference provides us to ...
(Date:8/2/2015)... (PRWEB) , ... August 03, 2015 , ... A new ... of some childhood cancers. The study is led by Kenneth G. Lucas, M.D. ... University of Louisville in collaboration with colleagues at Kosair Children’s Hospital and ...
(Date:8/2/2015)... ... 2015 , ... For many “would be” entrepreneurs, starting a new business can prove to ... to start a business.” Neither needs be a major obstacle. , The U.S. has ... a business and be successful. The risks of starting a business can be high but ...
(Date:8/2/2015)... ... August 02, 2015 , ... ... muscles and connective tissues of a woman’s pelvic organs (uterus, bladder, and ... straining, heavy lifting, obesity, constipation, multiple vaginal deliveries, genetics, smoking, and the ...
(Date:8/2/2015)... ... 02, 2015 , ... Molecular biologists in New South Wales say a protein ... has just posted an article on the new research. Click here to read ... Ki67 expression in tissue samples from 42 patients with peritoneal mesothelioma and found a ...
Breaking Medicine News(10 mins):Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5Health News:Minimally Invasive and Robotic Treatment for Pelvic Organ Prolapse Now Available from the Specialists at Women’s Excellence in Bladder Control 2Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2
... Pyratine-6(TM) and Pyratine XR(TM)NAPA, Calif., March 31 Senetek ... engaged in the development of technologies that target the ... quarter and year ended December 31, 2008. Revenue for ... with $26,471,000 reported in 2007. Revenues for the ...
... 31 The following is a statement by Lois ... Senate Majority Leader Smith and Assembly Speaker Silver for ... benefit under one of New York,s most beneficial programs ... program was in danger of losing more than $50 ...
... CITY, Mo., March 31 DST Systems, Inc. (NYSE: ... 50% of Argus Health Systems, Inc. ("Argus"). Argus is now ... in this press release may include forward-looking statements respecting DST ... DST,s views as of today, and actual actions or results ...
... DIEGO, March 31 - Orexigen(R) Therapeutics, Inc. (Nasdaq: ... on the treatment of obesity, today announced that ... as President and Chief Executive Officer of the ... M.D., Executive Chairman and Interim President and CEO. ...
... JACKSONVILLE, Fla., March 31 MSC ... products and services to post-discharge and post-injury workers, ... acquired Optimal Translation & Transportation, a national company ... acquisition further fortifies MSC,s position in the market, ...
... 31, 2009 -- Scientists who first established a link ... live in the intestine now are investigating whether the ... Researchers at Washington University School of Medicine in St. ... whether severely malnourished infants living in Malawi and Bangladesh ...
Cached Medicine News:Health News:Senetek PLC Reports 2008 Financial Results 2Health News:Senetek PLC Reports 2008 Financial Results 3Health News:State Budget Preserves State Pharmacy Program for Seniors (EPIC) 2Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 2Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 3Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 4Health News:MSC Acquires Optimal Translation & Transportation 2Health News:$5.5 million from Gates Foundation funds major study of childhood malnutrition 2Health News:$5.5 million from Gates Foundation funds major study of childhood malnutrition 3Health News:$5.5 million from Gates Foundation funds major study of childhood malnutrition 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: